Bortezomib 2’mg Injection in pakistan
ortezomib is a medication primarily used in the treatment of multiple myeloma, a type of blood cancer, and certain other conditions. It is a proteasome inhibitor, which means it works by interfering with the normal processes of cells, particularly cancer cells, to stop their growth and promote cell death. IMPORTENT NOTE... Those customers who belongs to lahore avail the opportunity of cash on delivery(COD) with in 30mints.
> ORIGNAL & IMPORTED.
Original price was: ₨6,999.00.₨5,999.00Current price is: ₨5,999.00.
Description
Bortezomib 2 mg Injection in Pakistan
Bortezomib 2 mg injection is used in Pakistan to treat multiple myeloma and mantle cell lymphoma in patients who have received prior therapy.
Dosage and Administration
- Recommended dose is 1.3 mg/m2 given intravenously (IV) or subcutaneously (SC) on days 1, 4, 8 and 11 of a 21-day cycle
- For IV, dilute to 1 mg/ml and give as a 3-5 second bolus injection
- For SC, inject at a 45-90° angle into the thighs or abdomen
Side Effects
Common side effects include fatigue, diarrhea, nausea, constipation, fever, peripheral neuropathy, and thrombocytopenia.
Key Benefits of Bortezomib 2 mg Injection
- Treats multiple myeloma and mantle cell lymphoma in patients who have received prior therapy
- Works by interfering with the growth and spread of cancer cells
Key Ingredients
- Active ingredient: Bortezomib
Storage
- Unopened vials: 20-25°C for up to 7 days
- Reconstituted: 25°C for up to 8 hours
- Total storage ≤8 hours under normal lighting                                      Key Side Effects of Bortezomib:
- Nausea, diarrhea
- Low blood cell counts (thrombocytopenia, neutropenia)
- Nerve damage (peripheral neuropathy)
- Fatigue, fever, appetite loss
Order site                                                                   Vitamins collection.com                                                      Contact                                                                    0307-7532291/0320-6421093
Reviews
There are no reviews yet.